Who founded Auxergen?

Auxergen was founded by Ting Yu-Yeh.

How much funding has Auxergen raised?

Auxergen has disclosed $535K raised across 1 round.

Where is Auxergen headquartered?

Auxergen is headquartered in Balitmore, US.

Auxergen

Balitmore, US · Delaware corporation

Find your way into Auxergen

Paths you didn't know you had: your email and LinkedIn already hold routes to the Auxergen team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Auxergen is an agricultural biotechnology R&D company developing biological treatments such as CitriPhage for citrus canker, bio-treatments for Olive Quick Decline Syndrome, and bioremediation and phage-based technologies. It operates within the University of Maryland incubator system and serves agriculture, human health, and environmental sustainability markets, with international operations including a subsidiary in Bari, Italy.

AgTech Biotech Cleantech Climate Tech

Founders & leadership

Ting Yu-YehCo-founder & Chief Science Officer

Gregory ContrerasCEO & Co-founder

Reported raises · per SEC filings

Form D private placements

$535K disclosed across 1 round · 2021

▶$535KraisedMay 2023 · 11 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Ting Yu-YehExecutive Officer, Director
Gregory ContrerasExecutive Officer, Director

Offering amount: $1M
Amount sold: $535K
Minimum investment: $25K
Proceeds to insiders: $420K
First sale: Apr 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 7

Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.

UrogenUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.

SolugenSolugen develops a biomanufacturing platform using fermentation and bioprocessing technology to produce specialty chemicals at scale. The company serves customers in energy, chemicals, and related industries with cost-effective alternatives to traditional petrochemical-based manufacturing.

WugenAllotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.

Macrogenics IncMacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients. It advances a pipeline of product candidates using proprietary platforms for antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.

VizgenVizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples. The company serves research and diagnostic laboratories in the life sciences and precision oncology fields.

CullgenCullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach. The company focuses on oncology and immune-related diseases and operates R&D and offices in both China and the United States.

Companies working in the same space as Auxergen.

Frequently asked questions

What does Auxergen do?: Auxergen is an agricultural biotechnology R&D company developing biological treatments such as CitriPhage for citrus canker, bio-treatments for Olive Quick Decline Syndrome, and bioremediation and phage-based technologies. It operates within the University of Maryland incubator system and serves agriculture, human health, and environmental sustainability markets, with international operations including a subsidiary in Bari, Italy.
Who founded Auxergen?: Auxergen was founded by Ting Yu-Yeh.
How much funding has Auxergen raised?: Auxergen has disclosed $535K raised across 1 round.
Where is Auxergen headquartered?: Auxergen is headquartered in Balitmore, US.